THERAPY DOSSIER · th-bbb6c57e7c7f

Histatin-1 (Hst1) peptide, alone or combined with acellular dermal matrix (ADM) paste

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32974320 ↗2020Reported benefit

Human Salivary Histatin-1 Is More Efficacious in Promoting Acute Skin Wound Healing Than Acellular Dermal Matrix Paste

MouseWoundC57 (C57BL)Malen = 48 mice across 8 treatment groups (6 per group)Topical applicationHst1 at 1, 10 or 50 μM; ADM alone; ADM + Hst1 at each conce…Applied starting at time of wounding

Model: Full-thickness excisional skin wound (1 cm punch biopsy, dorsal)

Topical 10 μM Hst1 significantly accelerated wound healing from day 3 to day 10, increased epidermal thickness and collagen deposition, increased CD31+ vessel density (2.3-fold) and VEGF expression, and reduced macrophage infiltration and pro-inflammatory markers versus control; ADM paste alone sho…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…